Sample size formulae for the Bayesian continual reassessment method
暂无分享,去创建一个
[1] Jianfen Shu,et al. Dose‐escalation designs in oncology: ADEPT and the CRM , 2008, Statistics in medicine.
[2] Ying Kuen Cheung. Commentary on ‘Small-sample behavior of novel phase I cancer trial designs’ , 2013, Clinical trials.
[3] M. Elkind,et al. Stochastic approximation with virtual observations for dose-finding on discrete levels. , 2010, Biometrika.
[4] Ying Kuen Cheung,et al. Calibration of prior variance in the Bayesian continual reassessment method , 2011, Statistics in medicine.
[5] Ying Kuen Cheung,et al. Sequential Implementation of Stepwise Procedures for Identifying the Maximum Tolerated Dose , 2007 .
[6] Anastasia Ivanova,et al. Escalation, group and A + B designs for dose‐finding trials , 2006, Statistics in medicine.
[7] C. Ahn,et al. An evaluation of phase I cancer clinical trial designs , 1998 .
[8] J O'Quigley,et al. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.
[9] Shing M. Lee,et al. Model calibration in the continual reassessment method , 2009, Clinical trials.
[10] Ying Kuen Cheung,et al. Two‐Stage Designs for Dose‐Finding Trials with a Biologic Endpoint Using Stepwise Tests , 2008, Biometrics.
[11] John O'Quigley,et al. Non-parametric optimal design in dose finding studies. , 2002, Biostatistics.
[12] Ying Kuen Cheung,et al. Coherence principles in dose-finding studies , 2005 .
[13] Y K Cheung,et al. Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities , 2000, Biometrics.
[14] John O'Quigley,et al. Consistency of continual reassessment method under model misspecification , 1996 .
[15] Jay Bartroff,et al. Approximate Dynamic Programming and Its Applications to the Design of Phase I Cancer Trials , 2010, 1011.6509.
[16] Ying Kuen Cheung,et al. A Simple Technique to Evaluate Model Sensitivity in the Continual Reassessment Method , 2002, Biometrics.
[17] J O'Quigley,et al. Continual reassessment method: a likelihood approach. , 1996, Biometrics.
[18] W J Shih,et al. Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials. , 2001, Biostatistics.
[19] M. Tighiouart,et al. Number of Patients per Cohort and Sample Size Considerations Using Dose Escalation with Overdose Control , 2012 .
[20] S. Durham,et al. A random walk rule for phase I clinical trials. , 1997, Biometrics.